Cardiovascular Disease


NOVO NORDISK RECRUITING STUDIES: • EX6018-4758 (ZEUS) – Cardiovascular risk/CKD/Inflammation This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. The study’s duration will last up to 4 [...]

Go to Top